Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP + Menveo
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP + Menveo refers to the concomitant administration of the DTaP (Diphtheria, Tetanus, and acellular Pertussis) vaccine and Novartis's quadrivalent meningococcal conjugate vaccine, Menveo (MenACWY-CRM). Menveo is a biologic vaccine containing capsular polysaccharides from *Neisseria meningitidis* serogroups A, C, W-135, and Y, each conjugated to a CRM197 carrier protein (a non-toxic mutant of diphtheria toxin). It is indicated for the prevention of invasive meningococcal disease. DTaP is a routine infant vaccine providing immunity against *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*. Clinical studies, such as the Phase 3 trial conducted by Novartis Vaccines (now part of GSK), evaluated the safety and immunogenicity of Menveo when administered concomitantly with routine pediatric vaccines like DTaP to ensure no interference in immune response and to support integrated vaccination schedules.
- Brand names
- MenveoInfanrixDaptacel
- Other names
- DTaP-Novartis Vaccines-meningococcal meningitisMeningococcal ACWY Conjugate VaccineMenACWY-CRM + DTaP
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on DTaP + Menveo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP + Menveo.